On 14 February 2018 and 16 February 2018, the World Trade Organization (WTO) conducted a Trade Policy Review (TPR) of Malaysia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes… Continue Reading
Brazil 1990-2000 Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16 2005 U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005. U.S. DoS… Continue Reading
After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading
On Friday, 20 October 2017, Brazil delivered the following statement during TRIPS Council discussions on compulsory licensing. Brazil zeroed in a recent compulsory licensing case in Germany involving raltagravir, an antiretroviral.
As reported by Knowledge Ecology International (KEI), on 6 June 2017, the World Trade Organization (WTO), published a paper tabled by Brazil, China, Fiji, India, and South Africa, entitled “Intellectual Property and the Public Interest.” In their communication (IP/C/W/630), the proponents called for a series of discussions at the WTO TRIPS Council on Intellectual Property and the Public Interest. Continue Reading
At the March 2017 session of the WTO TRIPS Council, Brazil delivered the following statement on copyright and e-commerce.
Copyright and e-commerce
Statement from Brazil
On 9 November 2016, the World Trade Organization’s (WTO) TRIPS Council held discussions on the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines (UN HLP). These timely WTO discussions on the UN HLP germinated from a 27 October 2016 request by Brazil, China, India and South Africa requesting the WTO Secretariat to place a dedicated agenda item for consideration at the 8-9 November 2016 session of the TRIPS Council entitled “the United Nations Secretary-General’s High-Level Panel Report on Access to Medicines.”
The following are selected cables from the US Department of State, obtained under the U.S. FOIA statutes, concerning patents and price negotiations on AIDS drugs. 2004 U.S. DoS Cable: GOB REACHES PRICING AGREEMENTS ON THREE MORE AIDS DRUGS – January… Continue Reading
Friday, 04 May 2007 Knowledge Ecology International Statement by James Love, +1202.361.3040, "Brazil's decision to issue a compulsory license on the patents for the AIDS drug efavirenz is an important first step to implement the Doha Declaration’s requirement that the… Continue Reading
Michel Lotrowska, a musician and health activist in Brazil, posted this informative note on Brazil’s latest announcement that it was considering a compulsory license on patents for a medicine — in this case, efavirenz, the BMS/Merck AIDS drug marketed by… Continue Reading